Sildenafil

Generic Name: Sildenafil

Brand Names: Liqrev, Revatio, Viagra, Vizarsin, Sildenafil Actavis, Sildenafil ratiopharm, Granpidam, Sildenafil Teva, Mysildecard

Drug Type: Small Molecule

Chemical Formula: C_₂₂H_₃₀N_₆O_₄S

CAS Number: 139755-83-2

Unique Ingredient Identifier: 3M7OB98Y7H

Background: In eliciting its mechanism of action, sildenafil ultimately prevents or minimizes the breakdown of cyclic guanosine monophosphate (cGMP) by inhibiting cGMP specific phosphodiesterase type 5 (PDE5) . The result of doing so allows cGMP present in both the penis and pulmonary vasculature to elicit smooth muscle relaxation and vasodilation that subsequently faci...

Indication: Sildenafil is a phosphodiesterase-5 (PDE5) inhibitor that is predominantly employed for two primary indications:

(1) the treatment of erectile dysfunction ; and

(2) treatment of pulmonary hypertension, where:
...

Associated Conditions: Erectile Dysfunction, NYHA Functional Class II-III Pulmonary arterial hypertension, Premature Ejaculation, Pulmonary Arterial Hypertension (PAH)

Associated Therapies: -

Clinical Trials

Topical Sildenafil as Pre-Treatment for Hand-Foot Skin Reaction

Early Phase 1

Completed

Conditions: Hand Foot Skin Reaction

Interventions: Drug: Sildenafil

First Posted Date: 2017-07-25

Last Posted Date: 2021-11-01

Lead Sponsor: Northwestern University

Target Recruit Count: 2

Registration Number: NCT03229512

Locations: 🇺🇸
Northwestern Memorial Hospital, Chicago, Illinois, United States
🇺🇸
Department of Dermatology, Northwestern University Feinberg School of Medicine, Chicago, Illinois, United States

Sildenafil To Prevent Clot

Early Phase 1

Completed

Conditions: Thrombosis
Hemolysis

Interventions: Drug: Placebo Oral Tablet
Drug: Sildenafil

First Posted Date: 2017-06-27

Last Posted Date: 2024-07-10

Lead Sponsor: Montefiore Medical Center

Target Recruit Count: 20

Registration Number: NCT03199612

Locations: 🇺🇸
Montefiore Medical Center, Bronx, New York, United States

Avanafil Versus Sildenafil in Spinal Cord Injury Erectile Dysfunction

Phase 4

Conditions: Erectile Dysfunction

Interventions: Drug: Sildenafil
Drug: Avanafil

First Posted Date: 2017-05-30

Last Posted Date: 2017-05-30

Lead Sponsor: Eduardo Vargas-Baquero

Target Recruit Count: 78

Registration Number: NCT03169582

Locations: 🇪🇸
Hospital Nacional de Paraplejicos, Toledo, Spain

Role of Sildenafil for Fontan Associated Liver Disease (SiFALD) Study

Phase 3

Completed

Conditions: Cirrhosis
Congenital Heart Disease

Interventions: Drug: Placebo
Drug: Sildenafil

First Posted Date: 2017-05-16

Last Posted Date: 2021-08-23

Lead Sponsor: Mayo Clinic

Target Recruit Count: 20

Registration Number: NCT03154476

Locations: 🇺🇸
Mayo Clinic in Rochester, Rochester, Minnesota, United States

Pharmacologically Triggered Migraine Without Aura and Neuroimaging

Not Applicable

Conditions: Migraine With Aura

Interventions: Drug: Placebo
Drug: Calcitonin Gene-Related Peptide
Drug: Sildenafil

First Posted Date: 2017-05-08

Last Posted Date: 2019-02-15

Lead Sponsor: Danish Headache Center

Target Recruit Count: 36

Registration Number: NCT03143465

Locations: 🇩🇰
Danish Headache Center, University Hospital, Glostrup, Denmark

Safety of Sildenafil in Premature Infants

Phase 2

Recruiting

Conditions: Bronchopulmonary Dysplasia

Interventions: Drug: Sildenafil
Other: Placebo

First Posted Date: 2017-05-05

Last Posted Date: 2024-12-18

Lead Sponsor: University of North Carolina, Chapel Hill

Target Recruit Count: 120

Registration Number: NCT03142568

Locations: 🇺🇸
University of Illinois at Chicago, Chicago, Illinois, United States
🇺🇸
University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States
🇺🇸
University of Florida Jacksonville Shands Medical Center, Jacksonville, Florida, United States

and more 14 locations

Use of Sildenafil for Treatment of Urinary Incontinence

Phase 1

Active, not recruiting

Conditions: Urinary Incontinence

Interventions: Drug: Placebo
Drug: Sildenafil

First Posted Date: 2016-12-06

Last Posted Date: 2024-03-12

Lead Sponsor: The University of Texas Medical Branch, Galveston

Target Recruit Count: 24

Registration Number: NCT02983461

Locations: 🇺🇸
University of Texas Medical Branch, Galveston, Texas, United States

Evaluation of Metabolic Markers for the Prediction of DDI of Various CYP3A Substrates and Inhibitors

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Sildenafil
Drug: Clarithromycin
Drug: Itraconazole

First Posted Date: 2016-11-29

Last Posted Date: 2022-10-27

Lead Sponsor: Seoul National University Hospital

Target Recruit Count: 32

Registration Number: NCT02975037

Locations: 🇰🇷
Seoul National University Hospital, Seoul, Korea, Republic of

Efficacy, Safety, and Tolerability Study of Pirfenidone in Combination With Sildenafil in Participants With Advanced Idiopathic Pulmonary Fibrosis (IPF) and Intermediate or High Probability of Group 3 Pulmonary Hypertension

Phase 2

Completed

Conditions: Idiopathic Pulmonary Fibrosis

Interventions: Drug: Pirfenidone
Drug: Placebo
Drug: Sildenafil

First Posted Date: 2016-11-01

Last Posted Date: 2020-11-12

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 177

Registration Number: NCT02951429

Locations: 🇳🇱
Vu Medisch Centrum; Afdeling Longziekten, Amsterdam, Netherlands
🇹🇷
Yedikule Gogus Hastaliklari ve Gogus Cerrahisi EAH;Gogus Hastaliklari, Istanbul, Turkey
🇿🇦
University of Stellenbosch; Respiratory Research, Parow, South Africa

and more 53 locations

Does Sildenafil Improve Endothelial Dysfunction in Rheumatoid Arthritis?

Phase 2

Terminated

Conditions: Arthritis, Rheumatoid
Atherosclerosis

Interventions: Drug: Sildenafil
Other: Placebo

First Posted Date: 2016-09-21

Last Posted Date: 2021-08-13

Lead Sponsor: Kimberly Liang

Target Recruit Count: 25

Registration Number: NCT02908490

Locations: 🇺🇸
University of Pittsburgh, Pittsburgh, Pennsylvania, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy